www.cotellic.com Open in urlscan Pro
2606:4700::6812:423  Public Scan

Form analysis
0 forms found in the DOM

Text Content

We are actively responding to the global COVID-19 pandemic. For more, please
visit our COVID-19 response page or call 1-877-436-3683.

The power of an immunotherapy can be added to COTELLIC + ZELBORAF9


Learn more about this combination and appropriate patients >

Contact a Rep Safety

For Patients and Caregivers
COTELLIC Prescribing Information COTELLIC Prescribing Information ZELBORAF
Prescribing Information ZELBORAF Prescribing Information Contact a Rep Contact a
Rep COTELLIC Patient Information COTELLIC Patient Information ZELBORAF
Medication Guide ZELBORAF Medication Guide Safety Safety
MENU

   
 * EFFICACY
    * TRIAL DESIGN
    * SURVIVAL DATA
    * RESPONSE DATA

 * DOSING
    * DOSAGE AND ADMINISTRATION
    * DOSE MODIFICATIONS

 * SAFETY
    * CLINICAL TRIAL SAFETY DATA
    * ADVERSE REACTIONS MONITORING

 * MOA
 * SUPPORT AND RESOURCES
    * ACCESS AND SUPPORT
    * RESOURCES LIBRARY

   

COTELLIC Prescribing Information ZELBORAF Prescribing Information Contact a Rep
COTELLIC Patient Information ZELBORAF Medication Guide Safety
For Patients and Caregivers



WE FOCUS ON ACCESS SO YOU CAN FOCUS ON HEALTH

At Genentech Access Solutions, we are dedicated to ensuring our medications are
accessible for the patients who need them. We can help your patients and
practice address each patient’s coverage scenario.

Start over Update response


 * Is your patient insured?
   
   Yes No

 * Does the patient's insurance cover his or her Genentech medicine?
   
   Yes No

 * Does your patient have commercial insurance?
   
   Yes No

 * Has your patient already been referred to the Genentech Oncology Co-pay
   Assistance Program and is either ineligible or no longer receiving
   assistance?
   
   Yes No

 * Has your patient already been referred to an independent co-pay assistance
   foundation and is either ineligible or no longer receiving assistance?
   
   Yes No

 * Is the patient 18 years of age or older?
   
   Yes No

Your Patient Might Qualify for a Referral to the Genentech Oncology Co-pay
Assistance Program

If eligible commercially insured patients need assistance with their
out-of-pocket costs, COTELLIC and ZELBORAF Access Solutions can refer them to
the Genentech Oncology Co-pay Assistance Program.*

 

Learn More

 

*Eligibility criteria apply. Not valid for patients using federal or state
government programs to pay for their medications and or administration of their
Genentech medication. Patient must be taking the Genentech medication for an
FDA-approved indication. See full Terms and Conditions at
CopayAssistanceNow.com.

Your Patient Might Qualify for a Referral to an Independent Co-pay Assistance
Foundation

For eligible patients with commercial or public health insurance, COTELLIC and
ZELBORAF Access Solutions offers referrals to independent co-pay assistance
foundations.*

 

Learn More

 

*Genentech does not influence or control the operations or eligibility criteria
of any independent co-pay assistance foundation and cannot guarantee co-pay
assistance after a referral from COTELLIC and ZELBORAF Access Solutions. The
foundations to which we refer patients are not exhaustive or indicative of
Genentech’s endorsement or financial support. There may be other foundations to
support the patient's disease state.

Your Patient Might Qualify for a Referral to the Genentech Patient Foundation

The Genentech Patient Foundation provides free Genentech medicine to people who
don't have insurance coverage or who have financial concerns and to people who
meet certain income criteria.*

 

Learn More

 

*To be eligible for free Genentech medicine from the Genentech Patient
Foundation, insured patients who have coverage for their medicine should try to
pursue other forms of financial assistance, if available, and meet certain
income requirements. Uninsured patients and insured patients without coverage
for their medicine must meet a different set of income requirements.


GENENTECH ACCESS TO CARE FOUNDATION (GATCF)

GATCF provides free medicine to eligible patients who are uninsured, rendered
uninsured by payer denial, or underinsured. To qualify, patients must meet
specific criteria. For more information, call (888) 249-4918 or
visit Genentech-Access.com/Oncology*.

*To be eligible for free medicine from GATCF, insured patients must have
exhausted all other forms of patient assistance (including Genentech
brand-specific co-pay cards and support from independent co-pay assistance
foundations) and meet additional criteria.


GENENTECH ONCOLOGY CO-PAY CARD

Commercially insured patients may be eligible for the Genentech Oncology Co-pay
Card† if they:

 * Are taking COTELLIC + ZELBORAF for an FDA-approved indication
 * Are over the age of 18
 * Do not have a government-funded health insurance plan (eg, Medicare, Medicare
   Advantage, Medicaid, TRICARE)
 * Are not receiving assistance from the GATCF or other charitable organizations
 * Do not reside in a state where co-pay cards are prohibited


†In order to be eligible for the Genentech Oncology Co-pay Card, the patient
must confirm that they meet the eligibility criteria and agree to the rules set
forth in the terms and conditions for the program. Please
visit CopayAssistanceNow.com for the full list of terms and conditions.


CO-PAY ASSISTANCE FOUNDATIONS

Genentech Access Solutions offers referrals to independent co-pay assistance
foundations‡ for eligible patients who are commercially or publicly insured,
including those covered by Medicare and Medicaid.

Key points to remember about independent co-pay assistance foundation referrals:

 * Eligibility requirements, all aspects of the application process, turnaround
   times and the amount of assistance offered can vary by foundation
 * If the patient is denied assistance by one co-pay assistance foundation, he
   or she can be referred to a different foundation, if one is available
 * Patients referred for co-pay assistance need not be enrolled in Genentech
   Access Solutions and can simply call for a referral


To view a list of potential independent co-pay assistance foundations,
visit Genentech-Access.com/Oncology.

‡Genentech does not influence or control the operations or eligibility criteria
of any independent co-pay assistance foundation and cannot guarantee co-pay
assistance after a referral from Genentech Access Solutions. The foundations to
which we refer patients are not exhaustive or indicative of Genentech's
endorsement or financial support. There may be other foundations to support the
patient's disease state.

Explore and download resources for your patients and your practice



VISIT THE RESOURCES LIBRARY

Get information about
financial assistance and more

VISIT GENENTECH-ACCESS.COM

IMPORTANT SAFETY INFORMATION & INDICATION

Back to Top


INDICATIONS AND USAGE

COTELLIC (cobimetinib) is indicated for the treatment of patients with
unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in
combination with ZELBORAF (vemurafenib).


IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Review the Full Prescribing Information for ZELBORAF for information on the
serious risks of ZELBORAF.

New Primary Malignancies

New primary malignancies, cutaneous and non-cutaneous, can occur with COTELLIC
in combination with ZELBORAF and with ZELBORAF as a single agent.

Cutaneous Malignancies

 * In Trial 1, the following cutaneous malignancies or premalignant conditions
   occurred in the COTELLIC with ZELBORAF arm and the ZELBORAF arm,
   respectively: cutaneous squamous cell carcinoma (cuSCC) or keratoacanthoma
   (KA) (6% and 20%), basal cell carcinoma (4.5% and 2.4%), and second primary
   melanoma (0.8% and 2.4%). Among patients receiving COTELLIC with ZELBORAF,
   the median time to detection of first cuSCC/KA was 4 months (range: 2 to 11
   months), and the median time to detection of basal cell carcinoma was 4
   months (range: 27 days to 13 months). The time to onset in the 2 patients
   with second primary melanoma was 9 months and 12 months.
 * Perform dermatologic evaluations prior to initiation of therapy and every 2
   months while on therapy. Manage suspicious skin lesions with excision and
   dermatopathologic evaluation. No dose modifications are recommended for
   COTELLIC. Conduct dermatologic monitoring for 6 months following
   discontinuation of COTELLIC when administered with ZELBORAF.

Non-cutaneous Malignancies

 * Based on its mechanism of action, ZELBORAF may promote growth and development
   of malignancies.
 * Monitor patients receiving COTELLIC, when administered with ZELBORAF, for
   signs or symptoms of non-cutaneous malignancies.

Other Malignancies

 * Based on its mechanism of action, ZELBORAF may promote malignancies
   associated with activation of RAS through mutation or other mechanisms.
 * Monitor patients receiving ZELBORAF closely for signs or symptoms of other
   malignancies.

Tumor Promotion in BRAF Wild-Type Melanoma

In vitro experiments have demonstrated paradoxical activation of MAP-kinase
signaling and increased cell proliferation in BRAF wild-type cells that are
exposed to BRAF inhibitors.

Hemorrhage

Hemorrhage, including major hemorrhages defined as symptomatic bleeding in a
critical area or organ, can occur with COTELLIC.

 * In Trial 1, the incidence of Grade 3-4 hemorrhages was 1.2% in patients
   receiving COTELLIC with ZELBORAF and 0.8% in patients receiving ZELBORAF.
   Hemorrhage (all Grades) was 13% in patients receiving COTELLIC with ZELBORAF
   and 7% in patients receiving ZELBORAF.
 * Withhold COTELLIC for Grade 3 hemorrhagic events. If improved to Grade 0 or 1
   within 4 weeks, resume COTELLIC at a lower dose level. Discontinue COTELLIC
   for Grade 4 hemorrhagic events and any Grade 3 hemorrhagic events that do not
   improve.

Cardiomyopathy

 * Cardiomyopathy, defined as symptomatic and asymptomatic decline in left
   ventricular ejection fraction (LVEF), can occur with COTELLIC. The safety of
   COTELLIC has not been established in patients with a baseline LVEF that is
   either below institutional lower limit of normal (LLN) or below 50%.
 * Grade 2 or 3 decrease in LVEF occurred in 26% of patients receiving COTELLIC
   with ZELBORAF and 19% of patients receiving ZELBORAF.
 * Evaluate LVEF prior to initiation, 1 month after initiation, and every 3
   months thereafter until discontinuation of COTELLIC. Manage events of left
   ventricular dysfunction through treatment interruption, reduction, or
   discontinuation. In patients restarting COTELLIC after a dose reduction or
   interruption, evaluate LVEF at approximately 2 weeks, 4 weeks, 10 weeks, and
   16 weeks, and then as clinically indicated.

Hypersensitivity Reactions

 * Anaphylaxis and other serious hypersensitivity reactions can occur during
   treatment and upon re-initiation of treatment with ZELBORAF. Severe
   hypersensitivity reactions included generalized rash and erythema,
   hypotension, and drug reaction with eosinophilia and systemic symptoms (DRESS
   syndrome).
 * Permanently discontinue ZELBORAF in patients who experience a severe
   hypersensitivity reaction.

Severe Dermatologic Reactions

COTELLIC:

 * Severe rash and other skin reactions can occur with COTELLIC. In Trial 1,
   Grade 3 to 4 rash occurred in 16% of patients receiving COTELLIC with
   ZELBORAF and in 17% of patients receiving ZELBORAF, including Grade 4 rash in
   1.6% of patients receiving COTELLIC with ZELBORAF and 0.8% of the patients
   receiving ZELBORAF.
 * Interrupt, reduce the dose, or discontinue COTELLIC for severe dermatologic
   reactions.

ZELBORAF:

 * Severe dermatologic reactions, including Stevens-Johnson syndrome and toxic
   epidermal necrolysis, can occur in patients receiving ZELBORAF.
 * Permanently discontinue ZELBORAF in patients who experience a severe
   dermatologic reaction.

Serous Retinopathy and Retinal Vein Occlusion

Ocular toxicities can occur with COTELLIC, including serous retinopathy (fluid
accumulation under layers of the retina).

 * Symptomatic and asymptomatic serous retinopathy was identified in 26% of
   patients receiving COTELLIC with ZELBORAF. The majority of these events were
   reported as chorioretinopathy (13%) or retinal detachment (12%).
 * Perform an ophthalmologic evaluation at regular intervals and any time a
   patient reports new or worsening visual disturbances. If serous retinopathy
   is diagnosed, interrupt COTELLIC until visual symptoms improve. Manage serous
   retinopathy with treatment interruption, dose reduction, or with treatment
   discontinuation.

QT Prolongation

 * Concentration-dependent QT prolongation occurred in an uncontrolled,
   open-label QT substudy of ZELBORAF in previously treated patients with BRAF
   V600E mutation-positive metastatic melanoma. QT prolongation may lead to an
   increased risk of ventricular arrhythmias, including Torsade de Pointes.
 * Do not start treatment with ZELBORAF in patients with uncorrectable
   electrolyte abnormalities, QTc >500 ms, or long QT syndrome, or in patients
   who are taking medicinal products known to prolong the QT interval. Prior to
   and following treatment initiation or after dose modification of ZELBORAF for
   QTc prolongation, evaluate ECG and electrolytes (including potassium,
   magnesium, and calcium) after 15 days, monthly during the first 3 months, and
   then every 3 months thereafter or more often as clinically indicated.
 * Withhold ZELBORAF in patients who develop QTc >500 ms (Grade 3). Upon
   recovery to QTc ≤500 ms (Grade ≤2), restart at a reduced dose. Permanently
   discontinue treatment with ZELBORAF if the QTc interval remains >500 ms and
   increased >60 ms from pretreatment values after controlling cardiac risk
   factors for QT prolongation (eg, electrolyte abnormalities, congestive heart
   failure, and bradyarrhythmias).

Hepatotoxicity


Hepatotoxicity can occur with COTELLIC in combination with ZELBORAF and with
ZELBORAF as a single agent.

 * The incidences of Grade 3 or 4 liver laboratory abnormalities in Trial 1
   among patients receiving COTELLIC with ZELBORAF compared with patients
   receiving ZELBORAF were 11% vs 5% for alanine aminotransferase, 8% vs 2.1%
   for aspartate aminotransferase, 1.6% vs 1.2% for total bilirubin, and 7% vs
   3.3% for alkaline phosphatase.
 * Liver injury leading to functional hepatic impairment, including coagulopathy
   or other organ dysfunction, can occur with ZELBORAF.
 * Monitor liver laboratory tests, including transaminases, alkaline
   phosphatase, and bilirubin, before initiation of COTELLIC in combination with
   ZELBORAF and monthly during treatment, or more frequently as clinically
   indicated. Manage Grade 3 or 4 liver laboratory abnormalities with dose
   interruption, reduction, or discontinuation of COTELLIC and ZELBORAF.

Concurrent Administration with Ipilimumab

The safety and effectiveness of ZELBORAF in combination with ipilimumab have not
been established.

Rhabdomyolysis

Rhabdomyolysis can occur with COTELLIC.

 * In Trial 1, Grade 3 or 4 creatine phosphokinase (CPK) elevations, including
   asymptomatic elevations over baseline, occurred in 14% of patients receiving
   COTELLIC with ZELBORAF and 0.5% of patients receiving ZELBORAF.
 * Obtain baseline serum CPK and creatinine levels prior to initiating COTELLIC,
   periodically during treatment, and as clinically indicated. If CPK is
   elevated, evaluate for signs and symptoms of rhabdomyolysis or other causes.
   Depending on the severity of symptoms or CPK elevation, dose interruption or
   discontinuation of COTELLIC may be required.

Severe Photosensitivity

Photosensitivity, including severe cases, can occur with COTELLIC in combination
with ZELBORAF and with ZELBORAF as a single agent.

 * In Trial 1, photosensitivity was reported in 47% of patients receiving
   COTELLIC with ZELBORAF: 43% of patients with Grades 1 or 2 photosensitivity
   and the remaining 4% with Grade 3 photosensitivity.
 * Advise patients to avoid sun exposure, wear protective clothing, and use a
   broad-spectrum UVA/UVB sunscreen and lip balm (SPF ≥30) when outdoors. Manage
   intolerable Grade ≥2 photosensitivity with dose modifications.

Other Ophthalmologic Reactions

 * Uveitis, blurry vision and photophobia can occur in patients treated with
   ZELBORAF.
 * Treatment with steroid and mydriatic ophthalmic drops may be required to
   manage uveitis. Monitor patients for uveitis.

Embryo-Fetal Toxicity

 * Based on its mechanism of action and findings from animal reproduction
   studies, COTELLIC can cause fetal harm when administered to a pregnant woman.
   Based on its mechanism of action, ZELBORAF can cause fetal harm when
   administered to a pregnant woman.
 * Advise pregnant women of the potential risk to a fetus. Advise females of
   reproductive potential to use effective contraception during treatment with
   COTELLIC and ZELBORAF and for 2 weeks after the final dose of COTELLIC or
   ZELBORAF (whichever is taken later).

Radiation Sensitization and Radiation Recall


 * Radiation sensitization and recall, in some cases severe, have been reported
   in patients treated with radiation prior to, during, or subsequent to
   ZELBORAF. Fatal cases have been reported in patients with visceral organ
   involvement.
 * Monitor patients closely when ZELBORAF is administered concomitantly or
   sequentially with radiation treatment.

Renal Failure

 * Renal failure, including acute interstitial nephritis and acute tubular
   necrosis, can occur with ZELBORAF.
 * Measure serum creatinine before initiation of ZELBORAF and periodically
   during treatment.

Dupuytren’s Contracture and Plantar Fascial Fibromatosis

 * Dupuytren’s contracture and plantar fascial fibromatosis have been reported
   with ZELBORAF. The majority of cases were mild to moderate, but severe,
   disabling cases have also been reported.
 * Events should be managed with dose reduction, treatment interruption, or
   treatment discontinuation.

USE IN SPECIFIC POPULATIONS: Lactation

Because of the potential for serious adverse reactions in a breastfed infant,
including malignancy, severe dermatologic reactions, QT prolongation,
hepatotoxicity, photosensitivity, and ophthalmologic toxicity from ZELBORAF,
advise women not to breastfeed during treatment with COTELLIC and ZELBORAF and
for 2 weeks after the final dose of COTELLIC or ZELBORAF (whichever is taken
later).

DRUG INTERACTIONS

COTELLIC:

 * Avoid concurrent use of strong or moderate CYP3A inhibitors.
 * Avoid concurrent use of strong or moderate CYP3A inducers including but not
   limited to carbamazepine, efavirenz, phenytoin, rifampin, and St. John’s
   Wort.

ZELBORAF:

 * Avoid coadministration with strong CYP3A4 inhibitors or strong inducers and
   replace these drugs with alternative drugs when possible.
 * Avoid concomitant use with drugs having a narrow therapeutic window that are
   predominantly metabolized by CYP1A2.
 * Avoid concurrent use of P-glycoprotein (P-gp) substrates known to have narrow
   therapeutic indices.

Most Common Adverse Reactions for COTELLIC

The most common (≥20%) adverse reactions with COTELLIC were diarrhea (60%),
photosensitivity reaction (46%), nausea (41%), pyrexia (28%) and vomiting (24%).
The most common (≥5%) Grade 3-4 laboratory abnormalities were increased GGT
(21%), increased CPK (14%), hypophosphatemia (12%), increased ALT (11%),
lymphopenia (10%), increased AST (8%), increased alkaline phosphatase (7%), and
hyponatremia (6%).

You may report side effects to the FDA at (800) FDA-1088 or
www.fda.gov/medwatch. You may also report side effects to Genentech at (888)
835-2555.

Please see both Full COTELLIC Prescribing Information and Full ZELBORAF
Prescribing Information for additional Important Safety Information.





Reference

 * * COTELLIC Prescribing Information. Genentech, Inc. 2016. 
     
     COTELLIC Prescribing Information. Genentech, Inc. 2016. 
   
   * Larkin J, Ascierto PA, Dréno B, et al. Combined vemurafenib and cobimetinib
     in BRAF-mutated melanoma. N Engl J Med. 2014;371:1867-1876.
     
     Larkin J, Ascierto PA, Dréno B, et al. Combined vemurafenib and cobimetinib
     in BRAF-mutated melanoma. N Engl J Med. 2014;371:1867-1876.
   
   * Data on file. Genentech, Inc.
     
     Data on file. Genentech, Inc.
   
   * ZELBORAF Prescribing Information. Genentech, Inc. 2017.
     
     ZELBORAF Prescribing Information. Genentech, Inc. 2017.
   
   * Department of Health and Human Services (DHHS). New Drug Application (NDA)
     approval 202429 [letter]. Food and Drug Administration. 2011.
     
     Department of Health and Human Services (DHHS). New Drug Application (NDA)
     approval 202429 [letter]. Food and Drug Administration. 2011.
   
   * Bollag G, Tsai J, Zhang J, et al. Vemurafenib: the first drug approved for
     BRAF-mutant cancer. Nat Rev Drug Discov. 2012;11:873-886.
     
     Bollag G, Tsai J, Zhang J, et al. Vemurafenib: the first drug approved for
     BRAF-mutant cancer. Nat Rev Drug Discov. 2012;11:873-886.
   
   * Santarpia L, Lippman SL, El-Naggar AK. Targeting the mitogen-activated
     protein kinase RAS-RAF signaling pathway in cancer therapy. Expert Opin
     Ther Targets. 2012;16:103-119.
     
     Santarpia L, Lippman SL, El-Naggar AK. Targeting the mitogen-activated
     protein kinase RAS-RAF signaling pathway in cancer therapy. Expert Opin
     Ther Targets. 2012;16:103-119.
   
   * Chen G, Davies MA. Targeted therapy resistance mechanisms and therapeutic
     implications in melanoma. Hematol Oncol Clin North Am. 2014;28:523-536.
     
     Chen G, Davies MA. Targeted therapy resistance mechanisms and therapeutic
     implications in melanoma. Hematol Oncol Clin North Am. 2014;28:523-536.
   
   * TECENTRIQ Prescribing Information. Genentech, Inc. 2020.
     
     TECENTRIQ Prescribing Information. Genentech, Inc. 2020.

Contact Us Privacy Policy Terms and Conditions Cookie Preferences Site Map

© 2022 Genentech USA, Inc. All rights reserved. This site is intended for U.S.
residents only.




LINK TO HEALTHCARE PROFESSIONALS SITE

Close

The information contained in this section of the site is intended for U.S.
healthcare professionals only. Click "OK" if you are a healthcare professional.

Cancel
OK



LINK TO THIRD PARTY SITE

Close

The link you have selected will take you away from this site to one that is not
owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation
as to the accuracy of the information contained on sites we do not own or
control. Genentech does not recommend and does not endorse the content on any
third-party websites. Your use of third-party websites is at your own risk and
subject to the terms and conditions of use for such sites.

Cancel
OK




OUR USE OF COOKIES

This website may use cookies and other technologies to personalize content and
advertisements on sites such as Google Ads, Facebook to you on this and other
websites and provide social media features on this website, including social
media sites such as Facebook, Twitter, LinkedIn. By accepting cookies, you
understand that you are directing Genentech to disclose data that may include
internet tracking data, cookies and the IP address you used to access this
website, which may be considered personal information, to these third parties
for the purposes stated above. You can still use this website if you do not
accept cookies, but your experience on this and other websites may be different.
You can always update these settings in your browser if you change your mind.
You also have the ability to customize your cookie preferences below. Privacy
Policy
Allow All


MANAGE CONSENT PREFERENCES

STRICTLY NECESSARY COOKIES

Always Active
Strictly Necessary Cookies

These cookies are necessary for the website to function and cannot be switched
off in our systems. They are usually only set in response to actions made by you
that amount to a request for services, such as setting your privacy preferences,
logging in, or filling in forms. You can set your browser to block or alert you
about these cookies, but blocking these cookies will prevent the site from
working. These cookies do not store any personal information.

PERFORMANCE COOKIES

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure and
improve the performance of our site. They help us to know which pages are the
most and least popular and see how visitors move around the site. We may provide
these cookies to third party service providers to help us run these analytics
(e.g. Google Analytics). All information these cookies collect is aggregated or
anonymized data and do not relate to you personally. If you block or opt out of
these cookies, we will not know when you have visited our site, and will not be
able to monitor its performance.

FUNCTIONAL COOKIES

Functional Cookies

These cookies enable our websites to provide enhanced functionality and
personalization. They may be set by us or by third party service providers whose
services we have added to our pages. If you reject these cookies, then some or
all of these services may not function properly.

SOCIAL MEDIA COOKIES

Social Media Cookies

These cookies may be set by a range of social media services that we may have
added to the site to enable you to share our content with your friends and
networks (such as Facebook, Twitter, LinkedIn). They are capable of tracking
your browser across other sites and building up a profile of your interests.
This may impact the content and messages you see on other websites you visit. If
you do not allow these cookies, you may not be able to use or see these sharing
tools.

TARGETING COOKIES

Targeting Cookies

These cookies may be set through our site by our advertising partners. They may
be used by those companies to build a profile of your interests and show you
relevant advertisements on other sites. They do not store directly personal
information, but are based on uniquely identifying your browser and internet
device. If you do not allow these cookies, you will experience less targeted
advertising.

Confirm My Choices

Back Button

Back


PERFORMANCE COOKIES

Vendor Search Search Icon Filter Icon


Clear Filters

Information storage and access
Apply
Consent Leg.Interest

All Consent Allowed

Select All Vendors
Select All Vendors
All Consent Allowed

Confirm My Choices